Factors to Consider in Prescribing Asthma Biologic Therapies to Children
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Factors to Consider in Prescribing Asthma Biologic Therapies to Children. / Anderson, William C.; Banzon, Tina M.; Chawes, Bo; Papadopoulos, Nikolaos G.; Phipatanakul, Wanda; Szefler, Stanley J.
I: Journal of Allergy and Clinical Immunology: In Practice, Bind 11, Nr. 3, 2023, s. 693-701.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Factors to Consider in Prescribing Asthma Biologic Therapies to Children
AU - Anderson, William C.
AU - Banzon, Tina M.
AU - Chawes, Bo
AU - Papadopoulos, Nikolaos G.
AU - Phipatanakul, Wanda
AU - Szefler, Stanley J.
N1 - Publisher Copyright: © 2023 American Academy of Allergy, Asthma & Immunology
PY - 2023
Y1 - 2023
N2 - The increasing availability of biologics, both by expanding age indications and by development of new therapies, provides additional options to treat children and adolescents with severe asthma. However, the evidence for these biologics in these populations is limited compared with that for adult studies. As such, before initiation of therapy, possible alternative therapies that can also provide asthma control, confirmation of the diagnosis of asthma, management of comorbidities, and assessment of adherence should be explored. The choice of a biologic should be a shared decision-making process between providers and families, balancing biologic efficacy, goals of care, administration, and ability to treat multiple conditions. Response to treatment should be periodically evaluated not only to ensure an ineffective treatment is not continued but also to consider when to potentially discontinue therapy should it be beneficial. The utilization of biologics in children and adolescents with severe asthma also leads to unanswered questions on their role in disease remission and long-term outcomes.
AB - The increasing availability of biologics, both by expanding age indications and by development of new therapies, provides additional options to treat children and adolescents with severe asthma. However, the evidence for these biologics in these populations is limited compared with that for adult studies. As such, before initiation of therapy, possible alternative therapies that can also provide asthma control, confirmation of the diagnosis of asthma, management of comorbidities, and assessment of adherence should be explored. The choice of a biologic should be a shared decision-making process between providers and families, balancing biologic efficacy, goals of care, administration, and ability to treat multiple conditions. Response to treatment should be periodically evaluated not only to ensure an ineffective treatment is not continued but also to consider when to potentially discontinue therapy should it be beneficial. The utilization of biologics in children and adolescents with severe asthma also leads to unanswered questions on their role in disease remission and long-term outcomes.
KW - Biologic
KW - Difficult-to-treat asthma
KW - Pediatric asthma
KW - Severe asthma
KW - Therapy
KW - Treatment
U2 - 10.1016/j.jaip.2022.12.038
DO - 10.1016/j.jaip.2022.12.038
M3 - Journal article
C2 - 36646381
AN - SCOPUS:85147284683
VL - 11
SP - 693
EP - 701
JO - The Journal of Allergy and Clinical Immunology: In Practice
JF - The Journal of Allergy and Clinical Immunology: In Practice
SN - 2213-2198
IS - 3
ER -
ID: 371204249